Global Scientific Investment with Mary Woolley, William Haseltine, Ellis Rubinstein and Alice Dautry at the 2007 Aspen Health Forum.
The United States no longer stands alone in either the actual conduct or the funding of scientific research. In today's world of increasingly multi-lateral medicine, how are we to get the most out of the ever-increasing investment in medical research and development? How are the best scientific partnerships forged? This session focuses on biotech investments around the globe and how, from business to academia, the capital markets can (and cannot) serve to promote efficient and productive research worldwide- Aspen Institute
Alice Dautry is President of Institut Pasteur, a post she has held since 2005. Dr. Dautry also is a professor and the head of the Biology of Cell Interaction Unit at the institute. She was trained as a solid state physicist at the University of Paris and as a molecular biologist at the University of New York at Stony Brook and the National Institutes of Health.
She has been a visiting scientist at the Massachusetts Institute of Technology and professor at Ecole Polytechnique. Her research focuses on cell biology, host-pathogen interactions, and cellular microbiology and receptors of the immune system, among other areas. She has also been very involved in educational activities, serving as director of the molecular biology of the cell graduate course at Institut Pasteur, teaching cell biology at Ecole Polytechnique, and training PhD students and postdoctoral fellows.
William A. Haseltine is chairman of Haseltine Global Health, LLC, a virtual pharmaceutical company dedicated to developing new and more efficient means to develop new life saving drugs and medical devices. He is also president of the Haseltine Foundation for Medical Sciences and the Arts, a foundation that supports access to high quality health for the poor and middle class of developing countries and that also fosters a dialog between sciences and the arts.
He is an adjunct professor at The Scripps Institute for Medical Research. Prior to his work as chairman, he was a professor at Harvard Medical School and chairman of Human Genome Sciences, Inc. He serves as a member of the board of trustees of several Foundations and NGOs and has been an advisor to several biotechnology and venture capital companies.
Jennifer Jarrett is a Director in the Health Care Group within the Credit Suisse Investment Banking Department, based in San Francisco. She has more than nine years of investment banking at Credit Suisse focused on biotechnology, with three years of investment banking at Merrill Lynch and Kidder Peabody. Ms. Jarrett received her MBA from Stanford University and her bachelor's from Dartmouth College.
Norman P. Neureiter is Director of the Center for Science, Technology and Security Policy at the American Association for the Advancement of Science, a post he has held since 2003. Prior to that, Dr. Neureiter was appointed as a Distinguished Presidential Fellow for International Affairs at the National Academy of Sciences, which followed his completion of a three-year assignment as the first Science and Technology Adviser to the U.S. Secretary of State. In 1973, Dr. Neureiter joined Texas Instruments (TI), where he held several positions, including Manager, East-West Business Development; Manager, TI Europe Division; Vice President, Corporate Staff; and Vice President of TI Asia, where he was resident in Tokyo for five years.
Ellis Rubinstein is President and CEO of the New York Academy of Sciences. Prior to this position, Mr. Rubinstein served as Editor of Science magazine with the American Association for the Advancement of Science. He also served as Editor of The Scientist and as a senior editor at Newsweek. During his three decades in journalism, he was thrice honored by the National Magazine Awards - the Pulitzer Prizes of the periodical industry.
Additionally, he wrote the most complete investigative report of the Three Mile Island nuclear power accident and a much cited investigative report on the true derivation of the cell line in which the AIDS virus was first grown.
Since 1990, Mary Woolley has been president and CEO of Research!America, the nation's largest not-for-profit alliance working to make research to improve health a higher national priority. Its 500+ organizational members represent the voices of 125 million Americans. Under her leadership, Research!America's membership has more than quadrupled as it has earned the attention and respect of research, media and community leaders with its signature public opinion polls and advocacy resource materials.
She is an elected member of the National Academy of Sciences' Institute of Medicine and fellow of the American Association for the Advancement of Science. She serves on the Harvard School of Public Health Board of Overseers and the IBM Life Sciences Council, among other volunteer activities. She has a 25-year editorial and publication history on science advocacy, policy and public opinion. She was educated at San Francisco State University and Stanford University and is a native of Chicago.